| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_87a863132c68cf0f62015bbd5d05ab38 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-41 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0676
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0613
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0696
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0735
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 |
| filingDate |
2010-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c586dc232cd31495c85859cb44847d2c |
| publicationDate |
2016-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MX-340952-B |
| titleOfInvention |
DIFFERENTIATION OF HUMAN EMBRYOUS MOTHER CELLS. |
| abstract |
The present invention relates to a process for conducting a molecular risk assessment (MRA) in a sample suspected of containing an enterohemorrhagic Escherichia coli (EHEC), comprising the steps: a) contacting said sample or DNA isolated therefrom. with a pair of primers derived from at least the following target genes: -stx1; .stx2; and at least one of the following target genes: -eae; -espK; and with a pair of primers derived from at least one of the following target genes: -nleB; nleH1-2; nleE; -ent / espL2; and detecting the presence or absence of an amplification product for each of said target genes; wherein the absence of one or more of the amplification products for said target genes indicates a low risk that the sample is contaminated with an EHEC strain, while the presence of an amplification product for each of said target genes indicates a high risk that the sample is contaminated with an EHEC strain; and if the amplification products for each of said genes from step a) are detected, then; b) contacting said sample or DNA isolated therefrom with one or more pairs of primers derived from the target eae gene and determining the eae subtype. |
| priorityDate |
2009-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |